<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231994</url>
  </required_header>
  <id_info>
    <org_study_id>EXCHANGE 2786-2015</org_study_id>
    <nct_id>NCT04231994</nct_id>
  </id_info>
  <brief_title>Therapeutic Plasmaexchange in Early Septic Shock</brief_title>
  <acronym>EXCHANGE</acronym>
  <official_title>Prospective, Randomized, Single-center, Open-label, Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy Against Early Septic Shock - Effect on Hemodynamics and Biochemical Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is defined by the occurrence of critical organ dysfunction in the context of
      infection. Unfortunately, its incidence appears to be rising, and the mortality of septic
      shock remains extraordinary high (&gt; 60%). Death in sepsis arises from shock and multi organ
      dysfunction that are - at least in part - triggered by an inadequate response of the host's
      immune system to the infection. Given the injurious role of 1) this overwhelming immune
      response and 2) the consumption of protective plasmatic factors (e.g. vWF cleaving proteases,
      hemostatic factors etc.) while the disease is progressing the investigators hypothesize that
      early therapeutic plasma exchange (TPE) in the most severely ill individuals might improve
      hemodynamics, oxygenation and ultimately survival. This therapeutic strategy combines 2 major
      aspects in 1 procedure: 1. removal of harmful circulating molecules and 2. replacement of
      protective plasma proteins. The investigators designed the EXCHANGE trial to analyze in a
      randomized fashion the benefit of TPE as an add-on treatment to state of the art standard
      sepsis care. Only patients with early septic shock (&lt; 24 hrs) and high catecholamine doses
      (norepinephrine &gt; 0.4 ug/kg body weight/min) will be included. Those in the treatment group
      will receive 1 TPE within 2 hours following randomization. The primary outcome is
      norepinephrine dose 6 hrs after randomization. The recruitment period is 2 years and will be
      performed at the Hannover medical School University hospital in Germany. Secondary endpoints
      (including organ dysfunction as well as biochemical markers of inflammation and coagulation)
      will be assessed on day 1-8 and day 28 after TPE.

      The investigators hope to demonstrate a potential benefit of an additive treatment approach
      to improve the outcome of patients suffering from septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Norepinephrine dose</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>Vasopressor dose reduction as indicator of shock reversal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>day 1-8 following randomization</time_frame>
    <description>SOFA score as indicator of organ dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of ADAMTS-13 activity from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>(will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of activated Protein C activity from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>(will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of permeability factors angiopoietin-1, -2 and sTie-2 from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>permeability and anti-permeability factors (will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day survival</measure>
    <time_frame>after 28 days following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balances</measure>
    <time_frame>6 hours before randomization, 6, 12 and 24 hours after randomization</time_frame>
    <description>net fluid balances in ml at various time points before and after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>TPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TPE</intervention_name>
    <description>singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid</description>
    <arm_group_label>TPE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of septic shock within less than 24 hrs

          -  Norepinephrine dose of ≥ 0.4 ug/kg/min bodyweight (target mean arterial pressure ≥ 65
             mmHg) ≥ 30 min

        Exclusion Criteria:

          -  Age&lt;18 years and &gt; 80 years

          -  Pregnancy

          -  Known history of transfusion reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Stahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for gastroenterology and hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sascha David, MD</last_name>
    <phone>00495115327632</phone>
    <email>david.sascha@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaus Stahl, MD</last_name>
    <phone>004915172405294</phone>
    <email>stahl.klaus@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha David, MD</last_name>
      <phone>00495115327623</phone>
      <email>david.sascha@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Klaus Stahl, MD</last_name>
      <phone>00495115327623</phone>
      <email>stahl.klaus@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chistian Bode, MD</last_name>
      <phone>49 (0) 228 287 14119</phone>
      <email>intensivmedizin@ukbonn.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Stahl, Klaus Dr.</investigator_full_name>
    <investigator_title>Dr. Klaus Stahl, Fellow Gastroenterology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Therapeutic plasma exchange</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>pre-defined substudies</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

